U.S. Markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.90 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.44 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.53
    -0.18 (-0.39%)
     
  • Gold

    1,788.10
    -23.10 (-1.28%)
     
  • Silver

    22.55
    -0.81 (-3.46%)
     
  • EUR/USD

    1.1960
    +0.0047 (+0.3947%)
     
  • 10-Yr Bond

    0.8460
    -0.0320 (-3.64%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3297
    -0.0059 (-0.4454%)
     
  • USD/JPY

    104.0320
    -0.2180 (-0.2091%)
     
  • BTC-USD

    16,834.97
    +110.17 (+0.66%)
     
  • CMC Crypto 200

    329.56
    -7.94 (-2.35%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets

·1 min read

SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2020 on Thursday, November 5, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through Tuesday, December 1, 2020.

To access the conference call, follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Conference ID: 5192707 (Nektar Therapeutics is the host)

About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology and immunology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contacts:

For Investors:
Jerry Isaacson of Nektar Therapeutics - 628-895-0634
Vivian Wu of Nektar Therapeutics - 628-895-0661

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-third-quarter-2020-on-thursday-november-5-2020-after-close-of-us-based-financial-markets-301162089.html

SOURCE Nektar Therapeutics